These include Crizotinib (NCT00939770) [144], ceritinib (NCT02336451) [111], and cabozantinib (NCT00704288) [224], as well as many investigational agents, such as brigatinib (ALK/ROS1) [39], entrectinib (ROS1/TRK) [128], and larotrectinib (TRK) [83, 194], the latter of which was recently approved in the treatment of TRK-altered cancers (NCT02122913) [83]. This evidence concerns the gene ROS1 and cancer.